STAT reporters discuss why drugmakers have not lobbied against RFK Jr.'s nomination to lead HHS and the struggles around ...
A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...
Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...
Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...
I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...
Medpage Today on MSN16h
Pulled Myeloma Drug Improves Survival in TrialA significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
according to new Phase II data presented at the American Society of Hematology's annual conference on Monday. Ciara Freeman, ...
Wells Fargo has downgraded Editas (EDIT) to equal weight, citing concerns about the potential positioning of reni-cel. Read more here.
Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback